Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
Abstract Molibresib (GSK525762) is an investigational, orally bioavailable, small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. Molibresib was initially evaluated in a first‐time‐in‐human (FTIH) study BET115521 consisting of two parts: Par...
Main Authors: | Anu Shilpa Krishnatry, Alexander Voelkner, Arindam Dhar, Marita Prohn, Geraldine Ferron‐Brady |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12639 |
Similar Items
-
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020-05-01) -
Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study
by: Ana‐Marija Grisic, et al.
Published: (2020-11-01) -
Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug‐Induced Hematotoxicity
by: Chiara Fornari, et al.
Published: (2020-09-01) -
Functionalized Surface Geometries Induce: “Bone: Formation by Autoinduction”
by: Ugo Ripamonti
Published: (2018-02-01) -
Valproic acid autoinduction: a case-based review
by: Sean Bennett, et al.
Published: (2021-09-01)